论文部分内容阅读
目的:探讨不同剂量瑞舒伐他汀对急性冠脉综合征患者(ACS)炎症反应及预后的影响。方法:选择2014年5月至2015年10月间收治的120例ACS患者为研究对象,随机分为A、B、C三组,每组40例。所有患者先给予常规治疗,A组患者给予20mg/d普伐他汀治疗;B组患者给予10 mg/d瑞舒伐他汀;C组患者给予20 mg/d瑞舒伐他汀,3组均持续治疗6个月。比较3组患者治疗前后血脂、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)的水平;随访6个月心血管事件发生情况。结果:3组患者治疗后hs-CRP、TNF-α、IL-6水平均明显下降,且C组下降最明显,其次为B组,比较差异均有统计学意义(P<0.05);治疗后血脂水平均的改善,且C组改善最明显,其次是B组,比较差异均有统计学意义(P<0.05);随访6个月,C组心血管事件发生率为2.5%,远低于B组(10.0%)及A组(20.0%),差异具有显著性(P<0.05)。结论:大剂量(20 mg/d)瑞舒伐他汀治疗ACS降脂、抗炎效果明显,预后相对较好,值得临床推广使用。
Objective: To investigate the effect of different doses of rosuvastatin on the inflammatory response and prognosis of patients with acute coronary syndrome (ACS). Methods: A total of 120 ACS patients admitted from May 2014 to October 2015 were selected as study subjects and randomly divided into three groups (A, B and C), 40 in each. All patients were given routine treatment, patients in group A received pravastatin 20 mg / d, patients in group B received rosuvastatin 10 mg / d, patients in group C received rosuvastatin 20 mg / d, and all patients in group C received continuous treatment 6 months. The levels of serum lipids, hs-CRP, TNF-α and IL-6 in the three groups were compared before and after treatment. The incidence of cardiovascular events at 6 months follow-up . Results: After treatment, the levels of hs-CRP, TNF-α and IL-6 in the three groups were significantly decreased, and the most obvious decrease was in group C, followed by group B, the differences were statistically significant (P <0.05) (P <0.05). After 6 months follow-up, the incidence of cardiovascular events in group C was 2.5%, which was much lower than that in group C Group B (10.0%) and Group A (20.0%), the difference was significant (P <0.05). Conclusion: High dose (20 mg / d) rosuvastatin can reduce blood lipid and anti-inflammatory effect of ACS, and its prognosis is relatively good, which is worthy of clinical promotion.